Search Results 271-280 of 15256 for TNF

1. Publications - Dan P. Larson, M.D. - Mayo Clinic

   Disseminated histoplasmosis and hemophagocytic lymphohistiocytosis in a patient receiving TNF-alpha inhibitor therapy. IDCases. 2022; 29:e01603. Epub 2022 ...

2. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   anti-TNF alpha agents) =< 2 weeks prior to randomization, or anticipation of need for systemic immunosuppressive medication during study treatment, with the ...

3. Publications - Clement J. Michet, Jr., M.D. - Mayo Clinic

   ... Tumor Necrosis Factor ... 2012 Mar; 18: (2)92-5. View PubMed; Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors ...

4. A Study to Assess the Effectiveness and Safety of Apremilast in Pediatric Patients (6 through 17 years old) with Moderate-to-Severe Plaque Psoriasis - Mayo Clinic

   Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to ...

5. Publications

   Publications. Shanafelt TD, West CP, Sinsky C, Trockel M, Tutty M, Wang H, Carlasare LE, Dyrbye LN. Changes in Burnout and Satisfaction With Work-Life ...

6. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   ... TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study. Note ...

7. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

   ... (TNF- a) inhibitors. * Medications that are under investigation for the treatment of IPF including inhaled treprostinil and Phosphodiesterase-4 (PDE-4) ...

8. Orhun H. Kantarci, M.D. - Mayo Clinic Faculty Profiles

   " They also have published the first open-label trial of using TNF-alpha inhibitors to successfully arrest Neuro-Behcet syndrome when other strategies fail for ...

9. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

   methotrexate, azathioprine, anti-tumor necrosis factor (TNF) agents, etc. with the exception of steroids - Administration of a live or live attenuated ...

10. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    ... TNF agents, and rituximab). Subjects with an MMT-8 score ≤ 66 (see Appendix B) must also have at least 2 other core set measures meeting the criteria ...